Robert Eisenbach

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Cooley advised Kim Kardashian, an American media personality, socialite and businesswoman, on SKIMS’ acquisition of SKKN by Kim, a beauty, skincare, and fragrance brand she founded, including the 20% stake held by Coty.

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).